Sio Capital Management LLC Acquires New Holdings in MBX Biosciences, Inc. $MBX

Sio Capital Management LLC acquired a new position in MBX Biosciences, Inc. (NASDAQ:MBX) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 241,000 shares of the company’s stock, valued at approximately $2,750,000. MBX Biosciences accounts for approximately 1.1% of Sio Capital Management LLC’s investment portfolio, making the stock its 24th largest position. Sio Capital Management LLC owned 0.72% of MBX Biosciences as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Woodline Partners LP lifted its position in shares of MBX Biosciences by 44.1% during the first quarter. Woodline Partners LP now owns 877,461 shares of the company’s stock worth $6,476,000 after purchasing an additional 268,740 shares in the last quarter. Parkman Healthcare Partners LLC grew its position in shares of MBX Biosciences by 93.1% in the 1st quarter. Parkman Healthcare Partners LLC now owns 328,323 shares of the company’s stock valued at $2,423,000 after purchasing an additional 158,323 shares during the period. Jump Financial LLC bought a new position in MBX Biosciences in the first quarter valued at approximately $214,000. Exome Asset Management LLC bought a new position in MBX Biosciences during the 1st quarter worth about $982,000. Finally, Walleye Capital LLC acquired a new stake in MBX Biosciences in the 1st quarter valued at approximately $240,000.

Insider Activity

In related news, Director Patrick J. Heron acquired 666,666 shares of the company’s stock in a transaction dated Friday, September 26th. The stock was bought at an average cost of $18.00 per share, with a total value of $11,999,988.00. Following the acquisition, the director owned 5,219,440 shares of the company’s stock, valued at approximately $93,949,920. The trade was a 14.64% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Steven L. Hoerter purchased 20,000 shares of the firm’s stock in a transaction on Friday, October 17th. The shares were acquired at an average cost of $13.25 per share, for a total transaction of $265,000.00. Following the completion of the purchase, the director directly owned 20,000 shares of the company’s stock, valued at approximately $265,000. This represents a ∞ increase in their position. The disclosure for this purchase is available in the SEC filing. In the last quarter, insiders have purchased 706,666 shares of company stock worth $12,537,788.

MBX Biosciences Stock Down 4.3%

NASDAQ MBX opened at $32.99 on Tuesday. MBX Biosciences, Inc. has a one year low of $4.81 and a one year high of $34.83. The business’s fifty day simple moving average is $21.05. The company has a market cap of $1.48 billion, a PE ratio of -13.80 and a beta of 0.71.

MBX Biosciences (NASDAQ:MBX) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($0.63) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.73) by $0.10.

Analyst Ratings Changes

A number of equities analysts have weighed in on MBX shares. Cowen began coverage on MBX Biosciences in a research report on Tuesday, November 4th. They set a “buy” rating on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of MBX Biosciences in a research note on Wednesday, October 8th. Guggenheim reduced their price target on MBX Biosciences from $84.00 to $77.00 and set a “buy” rating on the stock in a research report on Monday, November 10th. TD Cowen assumed coverage on MBX Biosciences in a report on Tuesday, November 4th. They issued a “buy” rating for the company. Finally, Mizuho upped their target price on MBX Biosciences from $38.00 to $56.00 and gave the stock an “outperform” rating in a research note on Wednesday, September 24th. Nine equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $49.50.

MBX Biosciences Profile

We are a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. Our company was founded by global leaders with a transformative approach to peptide drug design and development. Leveraging this expertise, we designed our proprietary Precision Endocrine Peptide™, or PEPTM, platform to overcome the key limitations of unmodified and modified peptide therapies and to improve clinical outcomes and simplify disease management for patients.